• Consensus Rating: Reduce
  • Consensus Price Target: $58.25
  • Forecasted Upside: -14.01%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$67.74
▲ +0.48 (0.71%)

This chart shows the closing price for SOLV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Solventum Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SOLV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SOLV

Analyst Price Target is $58.25
▼ -14.01% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Solventum in the last 3 months. The average price target is $58.25, with a high forecast of $64.00 and a low forecast of $54.00. The average price target represents a -14.01% upside from the last price of $67.74.

This chart shows the closing price for SOLV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 8 polled investment analysts is to reduce stock in Solventum. This rating has held steady since May 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
7/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
9/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
10/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/26/2024Wolfe ResearchInitiated CoveragePeer Perform
9/5/2024BTIG ResearchInitiated CoverageNeutral
8/12/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$48.00 ➝ $54.00
8/9/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$69.00 ➝ $64.00
7/15/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$70.00 ➝ $55.00
7/10/2024The Goldman Sachs GroupLower TargetSell ➝ Sell$54.00 ➝ $48.00
6/25/2024Bank of AmericaLower TargetNeutral ➝ Neutral$70.00 ➝ $60.00
6/24/2024ArgusInitiated CoverageHold
5/30/2024The Goldman Sachs GroupInitiated CoverageSell$54.00
5/10/2024Bank of AmericaInitiated CoverageNeutral$70.00
4/10/2024Morgan StanleyInitiated CoverageEqual Weight$70.00
4/8/2024Wells Fargo & CompanyInitiated CoverageEqual Weight$69.00
4/2/2024Edward JonesInitiated CoverageHold
(Data available from 10/4/2019 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/7/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/6/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/6/2024
  • 8 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/5/2024
  • 31 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2024
  • 31 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/4/2024

Current Sentiment

  • 31 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Solventum logo
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Read More

Today's Range

Now: $67.74
Low: $67.20
High: $68.41

50 Day Range

MA: $63.81
Low: $55.90
High: $72.33

52 Week Range

Now: $67.74
Low: $47.16
High: $96.05

Volume

836,828 shs

Average Volume

1,898,265 shs

Market Capitalization

$11.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Solventum?

The following Wall Street research analysts have issued research reports on Solventum in the last twelve months: Argus, Bank of America Co., BTIG Research, Edward Jones, Morgan Stanley, The Goldman Sachs Group, Inc., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for SOLV.

What is the current price target for Solventum?

4 Wall Street analysts have set twelve-month price targets for Solventum in the last year. Their average twelve-month price target is $58.25, suggesting a possible downside of 14.0%. Wells Fargo & Company has the highest price target set, predicting SOLV will reach $64.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $54.00 for Solventum in the next year.
View the latest price targets for SOLV.

What is the current consensus analyst rating for Solventum?

Solventum currently has 1 sell rating and 7 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for SOLV.

What other companies compete with Solventum?

Other companies that are similar to Solventum include Zimmer Biomet, Smith & Nephew, Penumbra, Bausch + Lomb and Glaukos. Learn More about companies similar to Solventum.

How do I contact Solventum's investor relations team?

The company's listed phone number is 651-733-1110 and its investor relations email address is [email protected]. The official website for Solventum is www.solventum.com. Learn More about contacing Solventum investor relations.